August 2025 FDA Recall Carvedilol by The Harvard Drug Group Llc Dba Major Pharmaceuticals And Rugby Laboratories
D-0594-2025 - CGMP Deviations

This Class II drug recall was voluntarily initiated by The Harvard Drug Group Llc Dba Major Pharmaceuticals And Rugby Laboratories on August 20, 2025 for the product Carvedilol. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0594-2025

Reason for Recall
CGMP Deviations: Results for N-Nitroso Carvedilol Impurity-1 (NNCI) impurity observed to be above the FDA-recommended limit of NMT 4.0 ppm
Initiated
08-20-2025
Reported
08-27-2025
Quantity
26,628 cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories
Product was distributed nationwide within the United States.
Carvedilol Tablets USP, 12.5 mg, 100- Tablets, (10x10) cartons, Rx Only, Packaged and distributed by Major Pharmaceuticals, Indianapolis, IN, 46268, USA, NDC 0904-7307-61

Batch or Lot Expiration Information

Lot# : T05693, Exp. Date 03/2026